Real Chemistry Introduces Iris: An Insights-as-a-Service Platform Delivering Timely Insights on the Obesity Market and the Growing Influence of GLP-1 Therapies
Fueled by the analysis of billions of data points using Real Chemistry’s proprietary AI, analytics and insights tools, IRIS offers a live dashboard and timely market reports.
- Fueled by the analysis of billions of data points using Real Chemistry’s proprietary AI, analytics and insights tools, IRIS offers a live dashboard and timely market reports.
- View the full release here: https://www.businesswire.com/news/home/20240430140657/en/
The IRIS platform offers a multi-dimensional and aggregated view across market performance, market access dynamics, the policy landscape, consumer behaviors and clinical milestones. - “No other therapeutic category has the emotional, psychological, physical, clinical, cultural and economic impact that treating obesity brings.
- Growing consumer-led, online communities are joining forces to navigate and advise others on managing market impacts, such as shortages and access.